The telehealth company Hims & Hers is adding Zepbound and generic liraglutide to its offering of weight-loss drugs.

OrderlyMeds, a provider of compounded versions of GLP-1 weight loss drugs, including Eli Lilly’s (NYSE:LLY) tirzepatide, said on Friday that a cease-and-desist letter sent by the pharma giant would ...

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research ...

Eli Lilly's foray into telehealth shows the emerging importance virtual care platforms are playing in the rising popularity ...

GLP-1 drugs are blockbuster medications for weight loss and Type 2 diabetes. Now doctors are trying them for lymphedema, ...

But this is just the start. GLP-1 drugs (specifically Novo Nordisk’s Ozempic, Rybelsus and Wegovy and Eli Lilly’s Mounjaro ...

People are buying semaglutide and tirzepatide, the key ingredients in Ozempic and Zepbound, from unconventional sources. Doctors have safety concerns.

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...

CompanyOverview|NYSE:HIMS] One of the more hotly debated stocks in the market, Hims & Hers Health (NYSE: HIMS), recently made ...

“One would expect that companies that pay dividends are more stable and have lower growth rates. As a result, they should rally less in up markets and decline less in down markets. In other words, ...

Eli Lilly is reaping the benefits from its innovation in diabetes and obesity management, with therapies like Mounjaro and ...

After massive gains in the past five years on the heels of the weight loss blockbuster Zepbound, Eli Lilly & Co (LLY) stock ...